High-end sequencing company Pacific Biosciences (PACB)
still has much left to prove. The company has done a good job of
improving system performance and reliability, but the 800lb gorilla in
the sequencing space, Illumina (ILMN), books more orders for both its HiSeq and MiSeq platforms in a quarter than PacBio has installed in the field. PacBio's alliance with Roche (OTCQX:RHHBY)
provided a significant boost to the stock, but it has yet to be
established that the company can develop systems and tests that will
work in the clinical diagnostics setting.
I continue to believe
that PacBio has a worthwhile future, as I believe the company can
address a multibillion-dollar opportunity by targeting applications
where Illumina's technology does not work as well. Microbial and plant
genetics, so-called "platinum genomes", and epigenetics are all areas
where PacBio's technology can play a long-term role. This is by no means
a stock for the nervous or impatient investor, but I believe
opportunity remains even after the large move in 2013.
Read the full article here:
Pacific Biosciences Looking To Carve Out Its Niche
No comments:
Post a Comment